The Therapeutic Efficacy of Tonsil-derived Mesenchymal Stem Cells in Dextran Sulfate Sodium-induced Acute Murine Colitis Model.
10.4166/kjg.2017.69.2.119
- Author:
Eun Mi SONG
1
;
Sung Ae JUNG
;
Ko Eun LEE
;
Ji Young JANG
;
Kang Hoon LEE
;
Chung Hyun TAE
;
Chang Mo MOON
;
Yang Hee JOO
;
Seong Eun KIM
;
Hye kyung JUNG
;
Ki Nam SHIM
Author Information
1. Department of Internal Medicine, Ewha Medical Research Institute, Ewha Womans University School of Medicine, Seoul, Korea. jassa@ewha.ac.kr
- Publication Type:Original Article
- Keywords:
Palatine tonsil;
Mesenchymal stem cells (MSC);
Inflammatory bowel disease
- MeSH:
Animals;
Body Weight;
Colitis*;
Colon;
Cytokines;
Dextran Sulfate*;
Dextrans*;
Inflammatory Bowel Diseases;
Interleukin-6;
Mesenchymal Stromal Cells*;
Mice;
Palatine Tonsil;
Stem Cells
- From:The Korean Journal of Gastroenterology
2017;69(2):119-128
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND/AIMS: Mesenchymal stem cells (MSCs) are multipotent progenitor cells currently under investigation for its efficacy as the treatment for inflammatory bowel disease. In this study, we evaluated the efficacy of tonsil-derived mesenchymal stem cells (T-MSCs) as a novel source of mesenchymal stem cells and traced their localization in a murine model of acute colitis induced by dextran sulfate sodium (DSS). METHODS: C57BL/6 mice were randomly assigned to the following three groups: the normal control group, DSS colitis group (DSS+phosphate buffered saline), and T-MSC group (DSS+T-MSCs, 1×106). The severity of colitis was assessed by determining the severity of symptoms of colitis, colon length, histopathologic grade, and levels of inflammatory cytokines. T-MSCs labeled with PKH26 were traced in vivo. RESULTS: The T-MSC group, compared with the DSS colitis group, showed a significantly lower disease activity index (11.3±1.5 vs. 8.3±1.9, p=0.015) at sacrifice and less reduction of body weight (-17.1±5.0% vs. -8.1±6.9%, p=0.049). In the T-MSC group, the histologic colitis score was significantly decreased compared with the DSS colitis group (22.6±3.8 vs. 17.0±3.4, p=0.039). IL-6 and IL-1β, the pro-inflammatory cytokines, were also significantly reduced after a treatment with T-MSCs. In vivo tracking revealed no PKH26-labelled T-MSCs in the colonic tissue of mice with acute colitis. CONCLUSIONS: In the acute colitis model, we demonstrated that the administration of T-MSCs ameliorates inflammatory symptoms and histology. Moreover, the anti-inflammatory activities of T-MSCs were independent of gut homing.
